Skip to content
Study details
Enrolling now

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institute on Deafness and Other Communication Disorders (NIDCD)
NCT IDNCT04915183ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

224

Study length

about 6.1 years

Ages

18–100

Locations

5 sites in GA, MD, NY +1

About this study

This trial is testing if atorvastatin can reduce hearing loss in people with head and neck cancer who are treated with cisplatin. Participants will take either atorvastatin or a placebo for a period of time, and their hearing will be monitored regularly to see if the medication helps prevent or lessen hearing loss.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take Atorvastatin
PhasePhase 2
DrugAtorvastatin
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

atorvastatin (Statin; inhibits HMG-CoA reductase to lower cholesterol)

Drug routes

oral

Endpoints

Secondary: To compare the incidence of grade (Bullet)3 AEs through 4 weeks after CRT with atorvastatin versus placebo., To examine the extent to which atorvastatin 40 mg alters overall survival and disease-free survival.

Body systems

Oncology